Rescheduling would make it easier for pharmaceutical companies to investigate the therapeutic potential of psilocybin and MDMA.
An aim to facilitate research“Unfortunately, regulatory red tape and a series of bureaucratic hurdles involved in studying Schedule I substances impedes critical research on these and other promising Schedule I compounds,” said Senator Booker in a news release. “This bill reduces these unreasonably burdensome rules and regulations that delay or prevent researchers from studying – and patients from accessing – this entire class of potential medicines.”
“This bill will make it easi…